Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.54 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21712949 | 0.98 | BAZ2B (0.53) | BAZ2BBAZ2AALDH1A1CYP1A2GAA | |
| SCHEMBL17992239 | 0.79 | GABRP (0.49) | BAZ2BBAZ2AALDH1A1CYP1A2GAA | |
| SCHEMBL8103043 | 0.78 | BAZ2B (0.53) | BAZ2BBAZ2AALDH1A1CYP1A2GAA | |
| SCHEMBL162449 | 0.78 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1CYP1A2GAA | |
| SCHEMBL21060866 | 0.78 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1CYP1A2GAA | |
| SCHEMBL70354 | 0.78 | BAZ2B (0.71) | BAZ2BBAZ2AALDH1A1CYP1A2GAA | |
| SCHEMBL5202768 | 0.78 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1CYP1A2GAA | |
| Hydrochloric Acid SCHEMBL653318 | 0.77 | BAZ2B (0.51) | BAZ2BBAZ2AALDH1A1CYP1A2GAA | |
| SCHEMBL20763689 | 0.76 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1CYP1A2GAA | |
| SCHEMBL1298467 | 0.76 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113039181-B | Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein | 勃林格殷格翰国际有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118373875-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2007005366-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060106069-A1 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-05-18 | — | — | US | disclosed |
| WO-2005113541-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6368608-B1 | SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) (FR) | 2002-04-09 | — | — | US | disclosed |
| US-6162445-A | Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-19 | — | — | US | disclosed |
| US-5723499-A | Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | C.I.R.D. GALDERMA (FR) | 1998-03-03 | — | — | US | disclosed |
| US-5716624-A | USEFUL FOR TREATING DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, OPTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS/DISORDERS | C.I.R.D. GALDERMA (FR) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | BAZ2B 577/4885BAZ2A 356/4885ALDH1A1 4701/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | BAZ2B 577/4885BAZ2A 356/4885ALDH1A1 4701/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | BAZ2B 513/4885BAZ2A 313/4885ALDH1A1 4718/4885 |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | BACE1, BACE2, APP | BAZ2B 30/4885BAZ2A 50/4885ALDH1A1 2693/4885 |
| US-20060106069-A1 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | MAP3K1, MAP4K2, MAP3K4 | BAZ2B 1491/4885BAZ2A 1343/4885ALDH1A1 2855/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | BAZ2B 577/4885BAZ2A 356/4885ALDH1A1 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.